Business Wire

Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats

Share

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19. With a grant totaling € 77.7 million, CARE is funded by cash contributions from the European Union (EU) and cash and in-kind contributions from eleven European Federation of Pharmaceutical Industries and Associations (EFPIA) companies and three IMI-Associated Partners. CARE is a five-year project bringing together 37 partners from Belgium, China, Denmark, France, Germany, the Netherlands, Poland, Spain, Switzerland, the UK and the US, and is led by VRI-Inserm (French National Institute of Health and Medical Research, Paris, France), Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Beerse, Belgium), and Takeda Pharmaceuticals International AG, (Zurich, Switzerland). It integrates partners’ COVID-19 projects ongoing since February 2020.

“The COVID-19 pandemic has emerged as the largest global health threat to humanity in this century, requiring the global scientific community to join forces in unprecedented ways,” said Professor Yves Lévy, Executive Director of the VRI-Inserm and CARE coordinator. “Beyond the scientific excellence of the different teams involved in this very ambitious project, CARE is bringing together 37 partners in an alliance pooling their expertise and know-how around an ambitious five-year work plan to develop therapeutics against the current COVID-19 pandemic. We are very grateful for the financial support provided by the Innovative Medicine Initiative that will enable us to implement this plan.”

With no licensed vaccines and only limited therapy options against COVID-19, the pandemic is ongoing, counting more cases and deaths every day. Uniting some of the most innovative and experienced scientists from all relevant areas in a unique collaborative spirit CARE will maximize synergies and complementarities with other initiatives such as the Gates Foundation-supported COVID-19 Therapeutics Accelerator, MANCO1, SCORE2, and the ECRAID3 network, to accelerate the path to providing solutions for the current COVID-19 pandemic as well as future coronavirus outbreaks. After testing in the laboratory, the project will advance the most promising drug candidates to clinical trials in humans.

We are very excited to launch the CARE consortium and collaborate with other leading experts to urgently identify new medicines against SARS-CoV-2 and other coronaviruses that may have the potential to cause epidemics,” added CARE project leader Marnix Van Loock, Senior Scientific Director and R&D Lead of Emerging Pathogens, Global Public Health, Janssen Pharmaceutica NV. “As part of this initiative, we look forward to applying learnings from an ongoing collaboration on COVID-19 with the Rega Institute for Medical Research, part of KU Leuven, to screen a drug repurposing library of thousands of existing drug compounds.”

Kumar Saikatendu, Ph.D., Director, Global Research Externalization, Takeda said “It is humbling to see such a large collection of the best scientific minds in Europe come together to solve this complex problem with such urgency. COVID-19 is a once in a lifetime scientific challenge for our generation. CARE aims to create effective therapies with a positive safety profile for current and future coronaviral outbreaks. We hope to move fast and have a meaningful impact in a timely manner.”

Comprehensive short- and long-term response to COVID-19

CARE aims to create effective therapies with a positive safety profile for the COVID-19 pandemic (drug repositioning), and develop new drugs and antibodies specially designed to tackle the SARS-CoV-2 virus.

The consortium builds on three pillars:

  • Drug repositioning, by screening and profiling compound libraries contributed by partners with the aim of rapidly progressing molecules to advanced stages of clinical testing.
  • Small-molecule drug discovery based on in silico screening and profiling of candidate compounds directed against SARS-CoV-2 and future coronavirus targets.
  • Virus neutralizing antibody discovery using fully human phage and yeast display, immunisation of humanised animal models, patient B cells and in silico design.

Closely integrated with these pillars are work streams focusing on the refinement of candidate compounds through a comprehensive medicinal chemistry campaign, systems biology research and pre-clinical and clinical evaluation of molecules from all three pillars. The systems biology work package will investigate the viral pathophysiology to increase our understanding of the interplay between virus infection stages and human immune responses. It will identify disease markers, to inform therapy development and improve clinical trial design and monitoring of Phase 1 and 2 trials investigating new therapeutics developed by CARE.

About CARE

CARE is a new public-private partnership bringing together scientists from academia, research centers, Small Medium Enterprises (SMEs), European Federation of Pharmaceutical Industries and Associations (EFPIA) member companies and IMI Associated Partners. In total, it comprises 37 different partner organizations. Professor Yves Lévy from VRI-Inserm is the academic coordinator, Marnix Van Loock from the Janssen Pharmaceutical Companies of Johnson & Johnson is the EFPIA project leader and Kumar Saikatendu from Takeda is the project co-leader. The project partners are 11 academic institutions (KUL, GUF, AMU, UzL UU, EDI-IVI, UHAM, UEDIN, TiHo, JU, LUMC), five public research organisations (Inserm, CHUV, CEA, HZI, SERMAS) and 7 SMEs (IT, EVF, EXSCI, NUVISAN, SCIFEON, ENYO, AIB), together with eleven EFPIA members (Janssen, Takeda, Pfizer, ABBV, BI, Merck KgA, BAG, Novartis, Astellas, Servier and AiCuris), and three IMI2 Associated Partners (BMGF, UNIVDUN, GHDDI).*

About Boehringer Ingelheim

About the IMI

Acknowledgement

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101005077. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, EFPIA, BILL & MELINDA GATES FOUNDATION, GLOBAL HEALTH DRUG DISCOVERY INSTITUTE, UNIVERSITY OF DUNDEE.

*Please click on the following link the List of partners: http://www.boehringer-ingelheim.com/press-release/launch-care-consortium

1 Monoclonal Antibodies against 2019-New Coronavirus

2 Swift Coronavirus therapeutics Response

3 European Clinical Research Alliance on Infectious Diseases

Contact information

Media Contacts:
For overarching questions re. CARE

Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com

Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
linda.ruckel@boehringer-ingelheim.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Orange Polska Leverages ADTRAN’s Fiber Extension Solutions to Extend FTTH Services30.9.2020 11:00:00 CESTPress release

https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fportal.adtran.com%2Fweb%2Fpage%2Fportal%2FAdtran%2Fwp_home&esheet=52297558&newsitemid=20200930005145&lan=en-US&anchor=ADTRAN%26%23174%3B%2C+Inc.&index=1&md5=a2f44128c043e79907dc3239808d7aba ADTRAN®, Inc., (NASDAQ:ADTN), the leading provider of next-generation open networking and subscriber experience solutions, today announced its deployment plans with Orange Polska. Orange, Poland’s leading operator with 28% market share and over 13.7 million active customers, is rapidly rolling out its Fiber-to-the-Home (FTTH) service and has selected https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.adtran.com%2Findex.php%2Fbroadband-access%2Fg-fast&esheet=52297558&newsitemid=20200930005145&lan=en-US&anchor=ADTRAN%26%238217%3Bs+2nd+Generation+Gfast+fiber+extension+solutions&index=3&md5=52a7e862db7c4f566a3e3be6b8e5e7a6 ADTRAN’s 2nd Generation Gfast fiber extension solutions to further accelerate its delivery of high

New Denodo Platform 8.0 Accelerates Hybrid/Multicloud Integration, Automates Data Management with AI/ML, and Boosts Performance30.9.2020 08:00:00 CESTPress release

Denodo, the leader in data virtualization, today announced that its new Denodo Platform version 8.0 accelerates hybrid/multicloud integration, automates data management with artificial intelligence (AI)/machine learning (ML), and boosts performance with smart query acceleration. By further augmenting the Denodo Platform’s already advanced data integration, management, and delivery capabilities with intelligent recommendations, hyper performance, and PaaS support, Denodo Platform 8.0 advances data virtualization into a logical data fabric. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005427/en/ “Data fabric is a hot, emerging market that delivers a unified, intelligent, and integrated end-to-end platform to support new and emerging use cases,” wrote Noel Yuhanna, VP and principal analyst at Forrester Research, and author of https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.denodo.com%2Fen%2Fforrest

Verimatrix Application Shielding Technology Wins CSI Magazine Award30.9.2020 07:15:00 CESTPress release

Regulatory News: Verimatrix, (Paris:VMX) (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that ProtectMyApp, an application shielding solution for mobile app developers, was named Best Cybersecurity Service in the 18th Annual CSI Magazine Awards. Winners were announced during a virtual broadcast on September 18. Verimatrix’s application shielding technology is routinely recognized for its ability to streamline the implementation of code protection while still providing the most robust security possible for mobile app developers. “It’s crucial to vigorously secure the actual mobile applications that have become such a vital part of our industry,” said Goran Nastic, editor of CSI Magazine. “Delivering increasingly valuable content, mobile apps and their developers can be armed with latest application shielding technologies that result in self-defending apps. Congratulations to Verimatrix for being named the winner of

Aurora Sustainability: Changing the World With the Network Effect30.9.2020 07:00:00 CESTPress release

«Be the change you want to see in the world,» is a well-worn cliché. However, most of us feel overwhelmed in the face of the climate and environmental challenges. Instead of giving in, Cape Town-based Danielle Laity and her team decided to do something. They’ve started a new community: Aurora Sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005910/en/ Danielle Laity's new sustainable network, Aurora Sustainability, started in Cape Town, and has already over 10.000 users. Credit: Miris (Photo: Business Wire) “In Cape Town, we feel the need for a more sustainable and fairer world every day. Food security is an issue, the predominantly fossil fuel based electrical grid is under strain and climate change will only exacerbate these problems” says Danielle Laity. On the Aurora community platform, anyone can log on and take a quick quiz that tells you the size of your carbon footprint. The intention is not to co

CellSafe and Dynasty Castle Investments Limited Signed Distribution Agreement for LAMPlex TM RT-qLAMP COVID-19 Detection Assay30.9.2020 06:44:00 CESTPress release

CellSafe, a specialist in developing diagnostics located at the Republic of Korea and Dynasty Castle Investments Limited, a Hong Kong based company specializing in the procurement, distribution and delivery of medical supplies, today announced that they have signed an exclusive distribution agreement for Portugal and 6 African countries for the sale and distribution of LAMPlexTM RT-qLAMP COVID-19 Detection Assay, real-time reverse transcription loop-mediated isothermal amplification (LAMP) technology-based kit which can detect the novel corona virus within 25 minutes. DCI has the rights to supply this clinically proven, reliable FAST molecular diagnostic kit in such countries in partnership with its local distributors. As this global pandemic is raging across the world, CellSafe has cooperated with Armed Forces Medical Research Institute, Republic of Korea to develop and launch LAMPlexTM RT-qLAMP COVID-19 Detection Assay. “This unprecedented pandemic is affecting our lives everywhere.

bitFlyer Europe Launches Cross-Border Trading with Japan to Further Consolidate Global Offering30.9.2020 06:00:00 CESTPress release

Leading cryptocurrency exchange bitFlyer has announced the launch of cross-border trading on its platform. For the first time, users in Europe will be able to access one of the largest bitcoin markets in Japan, while still using a European-regulated platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005920/en/ bitFlyer Europe launches cross-border trading with Japan (Graphic: Business Wire) The Japanese bitcoin market is one of the biggest in the world, with approximately 20%1 of the global BTC to FIAT (national currencies) trading volume being traded against the JPY. As Japan’s leading exchange, more than 70%2 of the JPY trading volume passes through the bitFlyer platform. This makes the launch of cross-border trading a natural next step for bitFlyer in consolidating its position as a global player. bitFlyer is now not only the first cryptocurrency exchange that is licensed to operate in Japan, the EU, and the U

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom